Why experts are warning parents not to give their kids dietary supplements like vitamins
ADVERTISEMENT
Parents should think twice before giving their children dietary supplements, a German consumer group warned after testing the ingredients of more than a dozen common products.
Supplements contain vitamins, minerals, and other nutrients and are intended as an add-on to a normal diet – but parents are also bombarded with conflicting messages about whether incorporating them into their child's diet will help or hurt their growth and development.
The Berlin-based consumer group Stiftung Warentest tested the ingredients of 18 common supplements against recommended nutrient intake levels for young people.
Related
Sugary drink consumption among kids climbed nearly 23% over three decades, study finds
It also analysed how they were advertised and whether their stated benefits were backed up by medical evidence.
The test team
flagged issues
with 17 of the supplements, with dosages above recommended levels for children in 15 of them. Five contained vitamin A at levels higher than the maximum recommendation for adults.
'Unnecessary at best, risky at worst'
Overall, Stiftung Warentest said, supplements for children are "unnecessary at best and risky at worst".
Food supplements are generally not considered necessary for healthy people with normal diets, and they aren't enough to make up for "one-sided, imbalanced" diets, according to the German Federal Institute for Risk Assessment (BfR), which does food safety assessments.
But supplements, which are regulated as food in the European Union, have become increasingly popular.
Related
Want to live better in old age? Scientists advise following these eating habits
A 2022 survey in 14 EU countries found that 93 per cent of adults had taken supplements in the past year, with most of them citing general health benefits.
When it comes to children, supplements are often billed as a way to boost kids' performance, development, or immune systems, according to BfR.
Those messages, the Stiftung Warentest analysis found, may not be entirely accurate.
"Manufacturers use enticing messages and suggestive images to make their products appealing to parents – sometimes using advertising claims that are illegal," the group said.
When supplements might be helpful
Meanwhile, Dr Berthold Koletzko, president of the European Academy of Paediatrics (EAP) and a paediatric gastroenterologist at the Ludwig Maximilian University of Munich, said the new conclusions are generally reasonable – but that they do not consider cases where vitamins and supplements might be beneficial for children.
Related
Body's internal clock could play a role in teens' late eating habits, researchers say
"Of course, you can get all the nutrients you need from a balanced diet," Koletzko told Euronews Health, adding that "most children don't need supplements".
However, he said, there are young children and adolescents with "suboptimal supplies of critical nutrients, and even deficiencies" of things like vitamin D, calcium, and omega-3 fatty acids.
ADVERTISEMENT
That's especially true if their
families are vegetarian,
gluten-free, or have another restrictive diet, Koletzko said, or if they live in a place without much sun.
A 2017 study, for example, found that 3.4 per cent of German children ages 6 to 17 were vegetarians, a level Koletzko expects has risen in the years since.
Related
Over 75% of 3 and 4-year-olds in Europe get too much screen time and not enough sleep and exercise
Even for children who could benefit from supplements, Koletzko said not all vitamins are created equal. Gummy vitamins, for example, are often high in sugar and run the risk of kids eating too many because they taste and look like sweets.
Children who get too many vitamins and minerals can experience stomach issues or loose stools.
ADVERTISEMENT
The bottom line, Koletzko said, is that parents worried about their child's nutritional status should seek guidance from a trusted health professional.
"It's important if you choose a supplement to select the right one and get advice from your paediatrician," Koletzko said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Euronews
2 days ago
- Euronews
Exclusive: At-home spit test certified as a contraceptive in Europe
A new at-home spit test appears to be as effective as birth control pills at preventing pregnancy – and it will soon roll out across Europe, Euronews Health has learned. The device from Inne, a Berlin-based women's health tech company, has been available for years as a fertility-monitoring tool designed to help people boost their chances of pregnancy. Called Minilab, it works by tracking users' progesterone, the sex hormone that plays a role in fertility, via daily changes in their saliva. Now, Minilab can also be used to prevent pregnancy, after a small study showed the device was 92 per cent effective – about on par with birth control pills, but without any of the side effects. 'Progesterone can be used for conception or contraception,' Eirini Rapti, Inne's chief executive and founder, told Euronews Health in an exclusive interview. But 'there was no reliable saliva testing' on the market, she said. So Rapti and her team decided to create it themselves. The British Standards Institution, which reviews medical device manufacturers in Europe, certified Inne's Minilab this month, meaning it can now be sold as a contraceptive device as well as a fertility tracker. Inne plans to roll out the device in the European Union in September, with sales in the United Kingdom to follow. The device is part of a new wave of women's health apps that have gained steam in recent years by infusing tech into fertility awareness, in a bid to make these contraceptive methods more effective, scientifically rigorous, and personalised. Key competitors like Natural Cycles – which, in 2017, became the EU's first certified contraceptive app – rely on temperature readings to track hormonal levels. But Rapti said saliva, as 'hardcore biological data,' is more accurate because it isn't affected by, for example, having a fever or working up a sweat. Meanwhile, blood tests are considered the gold standard for hormone tracking, but some research indicates saliva could be a promising alternative because it is cheaper, faster, and can be done easily at home. The Minilab device is fairly easy to use. Around the same time each day, the user spits into a test strip and inserts it into a small, sleek device that measures their progesterone. That data feeds back into an app, which learns about their hormonal fluctuations over time. That allows it to identify their fertile window, or the approximately six days per month when they are most likely to get pregnant. 'It's similar technology to COVID tests with antibodies, or pregnancy tests,' Rapti said. In the company's observational study, more than 200 women in Germany used the Minilab for six months. They were advised not to have unprotected sex on days the app said they were fertile, and asked to record their sexual activity. Eleven women got pregnant, but two were excluded from the analysis for violating the study guidelines. Others had unprotected sex on days the app identified as high risk for pregnancy, Rapti said. 'We did not have a case where our system gave the wrong ovulation day, or the wrong fertile day,' Rapti said. The findings translate to an effectiveness rate of 92 per cent, meaning that if 100 women used the Minilab as a contraceptive for one year, eight could expect to become pregnant. That's about the same as birth control pills or the contraceptive patch, and more effective than condoms (82 per cent). But it's far less effective than non-hormonal intrauterine devices (IUDs), sometimes called copper coils (more than 99 per cent). Notably, the study – which has not yet been published in a peer-reviewed, academic journal – did not include a control or comparison group, so Inne can't definitively prove that the device is what prevented pregnancy. Other methods of birth control have also been researched for decades, which means it can be difficult to directly compare Inne's results. But if the findings hold up over longer periods of time and with larger groups of people, it would make Minilab equally effective as Natural Cycles, the only other app-based contraceptive on the European market. The approach is also not for everyone. Women should not use Minilab if they have irregular menstrual cycles or were pregnant or breastfeeding within the past three months, the company said. It said women interested in switching from a hormonal contraceptive – such as birth control pills or certain IUDs – should wait at least two months before starting Minilab to allow their hormones to return to natural levels. Minilab already has thousands of users in Germany, Austria, and Switzerland, Rapti said. Eventually, she hopes to add testing for cortisol – the stress hormone – as well as testosterone and vitamins, to help women track their health throughout their lives, not only around pregnancy. 'If you have three or four years of data,' Rapti said, 'you can really start building some intelligence'. People who use cannabis or its synthetic cousin, cannabinoids, are twice as likely to die from heart problems as those who abstain from the drugs, new research has found. Recreational cannabis use remains illegal in most of Europe, but it is the region's most commonly used drug. An estimated 8.4 per cent of adults – 24 million people – used cannabis in the past year, according to the European Union Drugs Agency (EUDA). Cannabis is generally stronger and more diverse than in past decades, with users having a choice between smoking marijuana, edibles, cannabis concentrates, and cannabinoids, which are synthetic psychoactive drugs with a high concentration of Tetrahydrocannabinol (THC), the active ingredient in cannabis that makes people feel high. That has prompted concern about the potential health consequences of modern cannabis – and the new study, published in the journal Heart, is the latest to show they carry weight. In addition to the doubled mortality risks, cannabis use is tied to a 20 per cent higher risk of stroke and a 29 per cent higher risk of heart attacks or other types of acute coronary syndrome, which is when blood flow to the heart is severely restricted, the study found. The findings raise 'serious questions about the assumption that cannabis imposes little cardiovascular risk,' Stanton Glantz and Dr Lynn Silver, researchers at the University of California at San Francisco who were not involved with the study, said in a written comment. For the analysis, a French research team assessed real-world data from 24 studies conducted between 2016 and 2023. Most participants were between the ages of 19 and 59, and cannabis users were more likely to be younger and male compared with people who did not use the drug. Notably, most of the studies were observational, meaning researchers can't say that cannabis use causes heart problems directly. There was also a high risk of bias in most of the studies. More research is needed to understand exactly how cannabis is linked to heart problems, and whether the risks differ based on the type of cannabis someone uses. Despite the limitations, the study authors said their analysis is among the most comprehensive yet to probe the possible link between cannabis and heart problems in the real world. Glantz and Silver pushed for health warnings on cannabis products and protections against secondhand smoke exposure, particularly as countries relax their cannabis laws and the drug becomes more easily available. 'Cannabis needs to be incorporated into the framework for prevention of clinical cardiovascular disease,' they said.
France 24
3 days ago
- France 24
Canada needs 'bold ambition' to poach top US researchers
But to succeed, Canada will need to summon something it has at times lacked, namely "bold ambition," the head of the country's largest hospital chain told AFP. Trump's funding cuts for scientific research are freeing up talent and "creating a once-in-a-lifetime opportunity" to recruit, said Kevin Smith, the chief executive of Toronto's University Health Network (UHN). To seize that opportunity, Canada has to ditch its traditional "incrementalist" approach, Smith added. "Let's not say good enough is good enough. Let's say excellent is where we need to go." Experts say Trump's policies could trigger a tectonic shift in the global competition for the world's brightest minds. For decades, deep-pocketed US universities backed by federal support have scooped up talent, including in biomedical research. But Trump's administration has already slashed billions of dollars in research grants affecting various institutions, including most notably Harvard University. Programs affected by the National Institutes of Health's cuts include studies on gender, the health effects of global warming, Alzheimer's disease, and cancer. France and the European Union are already trying to woo disgruntled US researchers. European Commission head Ursula von der Leyen said last month that the EU would launch a new incentives package worth 500 million euros ($577 million) to make the 27-nation bloc "a magnet for researchers". 'Peanut butter spread' Smith and UHN's vice president for science and research, Brad Wouters, argued that Canada -- and particularly its largest city, Toronto -- are well placed to compete for US talent. English-speaking, culturally familiar, and geographically close to major US research centers in New England and New York, Toronto boasts a hospital network and research ecosystem regularly ranked among the world's best. The city has already poached three high-profile academics from Yale University, although all work in the arts. The group -- who study fascism -- announced last month in a stirring New York Times video that they were leaving the United States to take up positions in Toronto. "I'm leaving to the University of Toronto because I want to do my work without the fear that I will be punished," one of the professors, Jason Stanley, said in the video. Wouters told AFP that since Trump's election, UHN "started to see a talent pool that was a notch higher than what we normally see" for vacant positions, with leading US-based scientists initiating inquiries about opportunities in Toronto. UHN has launched a plan to create 100 medical research positions through its own fundraising but wants institutions across Canada to attract 1,000 new scientists. Reaching that target will require government support, and confronting an ingrained Canadian mindset that prioritizes sharing healthcare resources equally across the vast country. The plan will face "a bit of a collision between the peanut butter spread of equality versus elitism," Smith said. "That isn't always easy for governments or for elected we're pretty hopeful," he added. 'Supporting role' Matthew Lebo, a political scientist at Ontario's Western University, agreed Trump's policies have created an unprecedented opportunity for brain gain in Canada. But he voiced concern the country wouldn't mobilize. "Canada has a history of being comfortable playing a supporting role," he told AFP. "There is just an inherent lack of ambition." Lebo noted that while some US-based researchers may be concerned about crackdowns on their work, others might eye Canada for personal reasons, including the desire to live in a country where reproductive and LGBTQ rights are more firmly safeguarded. While he hasn't yet seen signs of broad national action, he said "it wouldn't take deep thought to catch up." "It takes some big number (of dollars) and a plan."
France 24
12-06-2025
- France 24
Germany's BioNTech to buy CureVac to boost cancer research
BioNTech, which developed the first coronavirus vaccine to be approved in the West along with US pharmaceutical giant Pfizer, said the acquisition would "bring together complementary capabilities and leverage technologies". Both biotech companies have been working for years in the area of mRNA vaccines and treatments, which provoke an immune response by delivering genetic molecules containing the code for key parts of a pathogen into human cells. While the technology became well known in relation to some Covid-19 vaccines, it is also being used in other areas, and scientists believe it could be a game-changer against many diseases. BioNTech said the acquisition of CureVac would help boost its work in the field of mRNA-based cancer immunotherapy -- treatment that uses the body's own immune system to fight diseases. "This transaction is another building block in BioNTech's oncology strategy and an investment in the future of cancer medicine," said BioNTech CEO Ugur Sahin. It was aimed at "establishing new standards of care for various types of cancer in the coming years," he said. Alexander Zehnder, CEO of CureVac, said the purchase would bring scientific expertise, technology and manufacturing know-how "in the mRNA field under one roof". BioNTech's all-stock acquisition has been unanimously approved by the companies' management and supervisory boards, and is expected to close in 2025, subject to certain conditions including regulatory approvals. Both companies are listed on the Nasdaq Composite Index. They had both sought to develop Covid-19 vaccines during the pandemic, with Mainz-based BioNTech's Comirnaty jab winning approval and going on to become one of the most widely used shots against the virus around the world. But Tuebingen-based CureVac, founded 25 years ago by mRNA pioneer Ingmar Hoerr, abandoned its efforts in late 2021 after disappointing trial results. In 2022, CureVac sued BioNTech for patent infringement over its rival's use of the technology.
